Talnetant

DB06429InvestigationalSmall molecule

Talnetant (SB-223,412) is a neurokinin 3 receptor antagonist developed by GlaxoSmithKline, which is being researched for several different functions, primarily for irritable bowel syndrome and as a potential antipsychotic drug...

Mechanism: Pharmacologically active on Neuromedin-K receptor
Curator reviewed
Primary indication: Investigated for use/treatment in schizophrenia and schizoaffective disorders, irritable bowel syndrome (IBS), and chronic obstructive pulmonary disease (COPD).Curator reviewed
Formula / weight: C₂₅H₂₂N₂O₂ · 382.4544 g/mol (avg)
Code names: SB-223412

Resolves to

Compound

UNIICZ3T9T146KCAS174636-32-9ChEMBLCHEMBL275544PubChem133090

Structure

InChIKeyBIAVGWDGIJKWRM-UHFFFAOYSA-NSMILESCCC(NC(=O)C1=C(O)C(=NC2=CC=CC=C12)C1=CC=CC=C1)C1=CC=CC=C1

Targets

P29371TACR3

What you can answer from here — as of September 23, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

8+ReferencesStructured and connected to the statements they support

Which drugs share a target with Talnetant, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account